Abstract: In one embodiment, a lidar system includes a light source configured to emit local-oscillator (LO) light and pulses of light, the emitted pulses of light including a first emitted pulse of light, where an optical frequency of the first emitted pulse of light is offset from an optical frequency of the LO light by a first frequency offset. The lidar system further includes a receiver configured to detect the LO light and a first received pulse of light, the first received pulse of light including light from the first emitted pulse of light scattered by a target located a distance from the lidar system. The receiver includes a detector, where: the LO light and the first received pulse of light are coherently mixed together at the detector, and the detector is configured to produce a photocurrent signal corresponding to the coherent mixing.

Abstract: In one embodiment, a lidar system includes a wavelength-tunable light source configured to emit pulses of light, each emitted pulse of light having a particular wavelength of multiple different wavelengths. The lidar system also includes a scanner configured to scan the emitted pulses of light across a field of regard of the lidar system. The scanner includes (i) a beam deflector configured to angularly deflect each emitted pulse of light along a first scan axis according to the particular wavelength of the emitted pulse of light and (ii) a scan mirror configured to scan the emitted pulses of light along a second scan axis different from the first scan axis. The lidar system further includes a receiver configured to detect a received pulse of light that includes a portion of one of the emitted pulses of light scattered by a target located a distance from the lidar system.

Abstract: S-11-hydroxy-10-methylaporphine and its biologically active salt forms are used as 5-HT.sub.1A inhibitors. Since these compounds function as 5-HT.sub.1A they can be used as an antidote for effects of cocaine and as appetite suppressants.

Abstract: Analogs and congeners of 4,4'-bis-[(1,3-dioxan-2-ylmethyl)aminoacetyl]biphenyl Dimethbromide. The compounds are effective antagonists of paraoxon induced toxicity and antagonized physiological response to certain nerve gas.

Abstract: Certain N,N-dialkyl substituted derivatives of dopamine (DA) increase renal blood flow without affecting cardiac contractility. Particularly effective are N,N-di-n-propyl DA; N-n-propyl-N-n-butyl DA; N-n-propyl-N-n-pentyl DA; N-n-propyl-N-isobutyl DA; and N-n-propyl-N-phenethyl DA. Orally effective versions of these derivatives are obtained by acylating the hydroxyl functions.

Abstract: Smooth muscle tissue relaxation is produced in mammals by internal administration of a compound of the formula: ##STR1## wherein R is alkyl having 1 to 6 carbon atoms, the novel compound 2-N-isopropylamino-1,2,3,4-tetrahydro-5,6,-dihydroxy-naphthalene being preferred. Relief of bronchial asthma and relaxation of the uterine smooth muscle are among the therapeutic effects produced.

Abstract: The compounds represented by the structural formulae: ##STR1## one each used for the treatment of warm blooded mammals with infarcted hearts.The compounds I and II have a totally unpredictable effect on the infarcted heart. An artificial infarct (stoppage of blood vessel) is produced, to mimic the occurrence of a heart attack. Administration of a suitable amount of the compound opens new blood channels in the heart tissue, by-passing the infarcted region, and providing a supply of arterial blood to the area served by the occluded blood vessel. The necrosis which normally occurs in regions of the heart muscle as a result of a stoppage of an artery and resultant oxygen deficiency is largely prevented.